Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera.
Maton
P N
PN
O'Dorisio
T M
TM
Howe
B A
BA
McArthur
K E
KE
Howard
J M
JM
Cherner
J A
JA
Malarkey
T B
TB
Collen
M J
MJ
Gardner
J D
JD
Jensen
R T
RT
D000138:Acidosis / Q000188:drug therapy / Q000209:etiology; D007516:Adenoma, Islet Cell / Q000150:complications* / Q000378:metabolism; D000368:Aged; D003967:Diarrhea / Q000188:drug therapy* / Q000209:etiology; D004351:Drug Resistance; D005260:Female; D006801:Humans; D007008:Hypokalemia / Q000188:drug therapy / Q000209:etiology; D007279:Injections, Subcutaneous; D007676:Kidney Failure, Chronic / Q000150:complications; D008297:Male; D009037:Motilin / Q000097:blood; D009496:Neurotensin / Q000097:blood; D015282:Octreotide; D010190:Pancreatic Neoplasms / Q000150:complications* / Q000378:metabolism; D010191:Pancreatic Polypeptide / Q000097:blood; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014660:Vasoactive Intestinal Peptide / Q000097:blood
D014660:Vasoactive Intestinal Peptide; D009496:Neurotensin; D013004:Somatostatin; D009037:Motilin; D010191:Pancreatic Polypeptide; D015282:Octreotide